Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apabetalone with Dapagliflozin in Long COVID and T2DM
NCT06590324Phase 3Recruiting
- Sponsor
- Resverlogix Corp.
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of apabetalone in post acute COVID-19 syndrome, sponsored by Resverlogix Corp. Primary endpoint: Patient Acceptable Symptom State at 90 days. Started Apr 2025; status: recruiting.
02
Drugs
apabetalone
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT06590324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590324.